Endostatin mutants with mutations at ATP binding sites
AssigneesTsinghua University, Beijing Protgen Ltd.
InventorsYongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
Life of this patent
Estimating the term…
Abstract
The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.
Claims6
A method of tumor therapy comprising administering to a subject having a tumor a mutant of human endostatin having the amino acid sequence set forth in SEQ ID NO:1 or of a human endostatin variant having the amino acid sequence set forth in SEQ ID No:2, 3 or 4, wherein said mutant has increased anti-angiogenesis activity as compared with the corresponding wild type endostatin or a variant thereof, wherein said mutant has decreased ATPase activity as compared with the corresponding wild type endostatin or a variant thereof, and wherein said mutant is selected from the group consisting of
- a) a mutant having the amino acid sequence set forth in SEQ ID NO:6,
- b) a mutant having the amino acid sequence set forth in SEQ ID NO:10,
- c) a mutant having the amino acid sequence set forth in SEQ ID NO:27, and
- d) a mutant having the amino acid sequence set forth in SEQ ID NO:30.
Dependencies are inferred from the claim text.